New combo therapy aims to improve survival in advanced nose cancer

NCT ID NCT07362979

First seen Jan 30, 2026 · Last updated Apr 25, 2026 · Updated 6 times

Summary

This study tests whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiation, can help people with advanced nasopharyngeal cancer live longer without the disease getting worse. About 243 adults aged 18-70 with stage T4N1 or any T with N2-3 cancer will be randomly assigned to one of three chemo combinations plus Toripalimab. The goal is to find the most effective regimen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Guangdong Medical University

    RECRUITING

    Zhanjiang, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen

    RECRUITING

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dongguan People's Hospital

    RECRUITING

    Dongguan, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.